Opinion
Video
Financial and Clinical Benefits of RSV Immunization
Author(s):
Following the recent approval of RSV vaccines, the panel discusses the financial and clinical benefits, highlighting the fiscal impact seen in hospitals and ICUs.
EP: 1.Overview of RSV Patient Populations
EP: 2.Complications Associated with RSV Infections
EP: 3.The Economic Burden and Main Drivers of Healthcare Resource Utilization in RSV
EP: 4.RSV: Risk Factors and How It’s Spread
EP: 5.Diagnostic Practices for RSV
EP: 6.Increasing Awareness of RSV Vaccines in At-Risk Patients
EP: 7.Shared Decision-Making Practices in RSV
Now Viewing
EP: 8.Financial and Clinical Benefits of RSV Immunization
EP: 9.The Potential Benefits of RSV Vaccine Approval for Adults Aged 50-59
EP: 10.Addressing Vaccine Fatigue
EP: 11.Identifying Patients Eligible for RSV Vaccine
EP: 12.Current and Potential Obstacles Related to Administering RSV Vaccines
EP: 13.Improving Insurance Coverage for RSV Vaccines
EP: 14.Improving RSV Vaccination Rates and Addressing Misinformation
EP: 15.Key Takeaways on RSV Vaccination
Video content above is prompted by the following questions:
- With RSV vaccines newly approved, what are the financial and clinical goals associated with immunizing against RSV?
- Have payers activated early coverage for the adult RSV vaccines since they entered to reduce costs?
- How have RSV vaccines altered the fiscal impact associated with managing RSV infections in hospitals or ICUs?
- How have RSV vaccines altered the fiscal impact associated with managing RSV infections in hospitals or ICUs?
Related Videos
Related Content
